Gait speed in clinical and daily living assessments in Parkinson’s disease patients: performance versus capacity

Abstract Gait speed often referred as the sixth vital sign is the most powerful biomarker of mobility. While a clinical setting allows the estimation of gait speed under controlled conditions that present functional capacity, gait speed in real-life conditions provides the actual performance of the...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Arash Atrsaei, Marta Francisca Corrà, Farzin Dadashi, Nuno Vila-Chã, Luis Maia, Benoit Mariani, Walter Maetzler, Kamiar Aminian
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/eb7bce135d2d4f298d2c62d03b4f59b7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:eb7bce135d2d4f298d2c62d03b4f59b7
record_format	dspace
spelling	oai:doaj.org-article:eb7bce135d2d4f298d2c62d03b4f59b72021-12-02T15:53:45ZGait speed in clinical and daily living assessments in Parkinson’s disease patients: performance versus capacity10.1038/s41531-021-00171-02373-8057https://doaj.org/article/eb7bce135d2d4f298d2c62d03b4f59b72021-03-01T00:00:00Zhttps://doi.org/10.1038/s41531-021-00171-0https://doaj.org/toc/2373-8057Abstract Gait speed often referred as the sixth vital sign is the most powerful biomarker of mobility. While a clinical setting allows the estimation of gait speed under controlled conditions that present functional capacity, gait speed in real-life conditions provides the actual performance of the patient. The goal of this study was to investigate objectively under what conditions during daily activities, patients perform as well as or better than in the clinic. To this end, we recruited 27 Parkinson’s disease (PD) patients and measured their gait speed by inertial measurement units through several walking tests in the clinic as well as their daily activities at home. By fitting a bimodal Gaussian model to their gait speed distribution, we found that on average, patients had similar modes in the clinic and during daily activities. Furthermore, we observed that the number of medication doses taken throughout the day had a moderate correlation with the difference between clinic and home. Performing a cycle-by-cycle analysis on gait speed during the home assessment, overall only about 3% of the strides had equal or greater gait speeds than the patients’ capacity in the clinic. These strides were during long walking bouts (>1 min) and happened before noon, around 26 min after medication intake, reaching their maximum occurrence probability 3 h after Levodopa intake. These results open the possibility of better control of medication intake in PD by considering both functional capacity and continuous monitoring of gait speed during real-life conditions.Arash AtrsaeiMarta Francisca CorràFarzin DadashiNuno Vila-ChãLuis MaiaBenoit MarianiWalter MaetzlerKamiar AminianNature PortfolioarticleNeurology. Diseases of the nervous systemRC346-429ENnpj Parkinson's Disease, Vol 7, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurology. Diseases of the nervous system RC346-429 Arash Atrsaei Marta Francisca Corrà Farzin Dadashi Nuno Vila-Chã Luis Maia Benoit Mariani Walter Maetzler Kamiar Aminian Gait speed in clinical and daily living assessments in Parkinson’s disease patients: performance versus capacity
description	Abstract Gait speed often referred as the sixth vital sign is the most powerful biomarker of mobility. While a clinical setting allows the estimation of gait speed under controlled conditions that present functional capacity, gait speed in real-life conditions provides the actual performance of the patient. The goal of this study was to investigate objectively under what conditions during daily activities, patients perform as well as or better than in the clinic. To this end, we recruited 27 Parkinson’s disease (PD) patients and measured their gait speed by inertial measurement units through several walking tests in the clinic as well as their daily activities at home. By fitting a bimodal Gaussian model to their gait speed distribution, we found that on average, patients had similar modes in the clinic and during daily activities. Furthermore, we observed that the number of medication doses taken throughout the day had a moderate correlation with the difference between clinic and home. Performing a cycle-by-cycle analysis on gait speed during the home assessment, overall only about 3% of the strides had equal or greater gait speeds than the patients’ capacity in the clinic. These strides were during long walking bouts (>1 min) and happened before noon, around 26 min after medication intake, reaching their maximum occurrence probability 3 h after Levodopa intake. These results open the possibility of better control of medication intake in PD by considering both functional capacity and continuous monitoring of gait speed during real-life conditions.
format	article
author	Arash Atrsaei Marta Francisca Corrà Farzin Dadashi Nuno Vila-Chã Luis Maia Benoit Mariani Walter Maetzler Kamiar Aminian
author_facet	Arash Atrsaei Marta Francisca Corrà Farzin Dadashi Nuno Vila-Chã Luis Maia Benoit Mariani Walter Maetzler Kamiar Aminian
author_sort	Arash Atrsaei
title	Gait speed in clinical and daily living assessments in Parkinson’s disease patients: performance versus capacity
title_short	Gait speed in clinical and daily living assessments in Parkinson’s disease patients: performance versus capacity
title_full	Gait speed in clinical and daily living assessments in Parkinson’s disease patients: performance versus capacity
title_fullStr	Gait speed in clinical and daily living assessments in Parkinson’s disease patients: performance versus capacity
title_full_unstemmed	Gait speed in clinical and daily living assessments in Parkinson’s disease patients: performance versus capacity
title_sort	gait speed in clinical and daily living assessments in parkinson’s disease patients: performance versus capacity
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/eb7bce135d2d4f298d2c62d03b4f59b7
work_keys_str_mv	AT arashatrsaei gaitspeedinclinicalanddailylivingassessmentsinparkinsonsdiseasepatientsperformanceversuscapacity AT martafranciscacorra gaitspeedinclinicalanddailylivingassessmentsinparkinsonsdiseasepatientsperformanceversuscapacity AT farzindadashi gaitspeedinclinicalanddailylivingassessmentsinparkinsonsdiseasepatientsperformanceversuscapacity AT nunovilacha gaitspeedinclinicalanddailylivingassessmentsinparkinsonsdiseasepatientsperformanceversuscapacity AT luismaia gaitspeedinclinicalanddailylivingassessmentsinparkinsonsdiseasepatientsperformanceversuscapacity AT benoitmariani gaitspeedinclinicalanddailylivingassessmentsinparkinsonsdiseasepatientsperformanceversuscapacity AT waltermaetzler gaitspeedinclinicalanddailylivingassessmentsinparkinsonsdiseasepatientsperformanceversuscapacity AT kamiaraminian gaitspeedinclinicalanddailylivingassessmentsinparkinsonsdiseasepatientsperformanceversuscapacity
_version_	1718385545633071104

Gait speed in clinical and daily living assessments in Parkinson’s disease patients: performance versus capacity

Ejemplares similares